AllianceBernstein
AVBP icon

AllianceBernstein’s ArriVent BioPharma AVBP Stock Holding History

AllianceBernstein’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$567K Hold
28,200
– – ﹤0.01% 2576
2025
Q4 		$567K Hold
28,200
– – ﹤0.01% 2598
2025
Q3 		$520K Hold
28,200
– – ﹤0.01% 2650
2025
Q2 		$614K Hold
28,200
– – ﹤0.01% 2522
2025
Q1 		$521K Hold
28,200
– – ﹤0.01% 2538
2024
Q4 		$751K Hold
28,200
– – ﹤0.01% 2464
2024
Q3 		$663K Buy
+28,200
New +$640K ﹤0.01% 2523

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AllianceBernstein's AVBP Position: Q1 2026 in Review

AllianceBernstein held its ArriVent BioPharma (AVBP) position steady in Q1 2026 at 28,200 shares worth $567K. The position accounts for ﹤0.01% of the portfolio, ranked #2576.

AllianceBernstein first reported a position in AVBP in Q3 2024 and has held it in 7 quarters since. The position peaked at $751K in Q4 2024. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • AllianceBernstein held 28,200 shares of ArriVent BioPharma worth $567K as of Q1 2026.
  • AllianceBernstein left its ArriVent BioPharma share count unchanged in Q1 2026.
  • ArriVent BioPharma made up ﹤0.01% of AllianceBernstein's portfolio in Q1 2026, its #2576 holding.
  • AllianceBernstein first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 7 quarters since.
  • AllianceBernstein's ArriVent BioPharma position peaked at $751K in Q4 2024.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.